You are here

lixivaptan

Palladio bags $20 million Series B to topple a problematic kidney disease drug

Endpoints

Fri, 09/25/20 - 10:33 am

Palladio Biosciences

autosomal dominant polycystic kidney disease

Cornerstone Therapeutics says FDA advisers recommend against approving its drug lixivaptan

Yahoo/AP

Thu, 09/13/12 - 04:10 pm

Cornerstone Therapeutics

Is This Drug Taking on Water?

Motley Fool

Thu, 09/13/12 - 10:08 am

Cornerstone Therapeutics

Gilead, Salix, Peregrine, Navidea Approach Key Dates In September

Minyanville

Tue, 09/4/12 - 12:27 pm

Peregrine Pharmaceuticals

Navidea Biopharmaceuticals

Cornerstone Therapeutics